A new oral drug developed by the pharmaceutical AstraZeneca significantly reduces the tumor progression in women with breast cancer with estrogen receptor (ER) positive and HER2 negative. The drug is called camizestrant and a phase two trial (Serena-2), coordinated by the Vall d’Hebron Institute of Oncology (VHIO), has just demonstrated that it improves progression-free survival […]
